1. Prognostic value of low microRNA-34a expression in human gastrointestinal cancer: a systematic review and meta-analysis.
- Author
-
Chen, Yan-Ling, Liu, Xiao-Lin, and Li, Ling
- Subjects
- *
GASTROINTESTINAL cancer , *PROGNOSIS , *LYMPHATIC metastasis , *PROGRESSION-free survival , *CANCER prognosis , *RNA metabolism , *RESEARCH , *META-analysis , *RESEARCH methodology , *SYSTEMATIC reviews , *RNA , *EVALUATION research , *GASTROINTESTINAL tumors , *COMPARATIVE studies , *GENES , *RESEARCH funding - Abstract
Background: Mounting evidence shows that microRNA-34a (miR-34a) is involved in cancer prognosis. Therefore, we summarize the predictive role of miR-34a for survival in patients with gastrointestinal cancers (GICs).Methods: All eligible studies were found by searching PubMed, Web of Science and EMBASE, and survival results were extracted. Then, the hazard ratio (HR) with the corresponding 95% confidence interval (CI) was calculated to evaluate the prognostic role of miR-34a in GICs. The association between miR-34a expression and clinicopathological characteristics was estimated by odds ratios (ORs) and 95% CIs.Results: A total of 20 studies were included in this meta-analysis. For overall survival (OS), lower miR-34a expression could probably predict poorer outcome in GICs, with a pooled HR of 1.86 (95% CI: 1.52-2.28, P < 0.01). For disease-free survival (DFS), progression-free survival (PFS), and recurrence-free survival (RFS), lower miR-34a expression was related to worse DFS/PFS/RFS with a pooled HR of 1.86 (95% CI: 1.31-2.63, P < 0.01). A significant relation of differentiation/TNM stage/lymphatic metastasis and the expression level of miR-34a was identified.Conclusion: This meta-analysis revealed that lower miR-34a expression is significantly connected with worse OS and DFS/PFS/RFS in GIC patients. In addition, the miR-34a expression level is relatively lower in patients with lymph node metastasis than in patients without lymph node metastasis, and decreased miR-34a expression levels are linked to poor tumour differentiation and late TNM stage. MiR-34a may become a new factor for the prognosis prediction and progression of GICs. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF